After more than five years of litigation, Bayer (BAYRY) and Johnson & Johnson (JNJ) agreed to pay $775 million to settle about 25,000 lawsuits over claims they failed to warn about side effects associated with the Xarelto blood thinner, which the companies jointly market.

The settlement, which will be split evenly between the drug makers, resolves both federal and state cases that alleged the companies downplayed potentially fatal risks of internal bleeding and aggressively marketed the drug as an alternative to warfarin for people who sought to avoid blood clots. Neither of the companies admitted liability, although both noted they prevailed in six cases that went to trial.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy